|
| Authors |
Title |
Citation |
Core tip / conclusive remarks |
|
|
| Chen W, Zhang H, Li Z, Deng Q, Wang M, Chen Y, Zhang Y. |
Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke. |
BMC Neurol. 2024 Jun 20; 24(1):209. |
Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels. |
|
| Xiao P, Huang H, Zhao H, Liu R, Sun Z, Liu Y, Chen N, Zhang Z. |
Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling. |
Free Radic Biol Med. 2024 May 1; 217:116-125. |
This study revealed for the first time that Eda.B safeguarded the BBB from cerebral I/R injury by inhibiting ferroptosis through the activation of the Nrf-2/HO-1/GPX4 axis, providing a novel insight into the neuroprotective effect of Eda.B in cerebral I/R. |
|
| Wang C, Gu HQ, Dong Q, Xu A, Wang N, Yang Y, Wang F, Wang Y. |
Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomized controlled trial. |
Stroke Vasc Neurol. 2024 Mar 11: svn-2023-002938. |
Edaravone, approved to treat amyotrophic lateral sclerosis by the US Food and Drug Administration, has proven to be cytoprotective through early scavenging of free radicals and later exerting anti-inflammatory effects to promote functional recovery and structural integrity in reperfusion animal models. |
|
| Wang D, Wang Y, Shi J, Jiang W, Huang W, Chen K, Wang X, Zhang G, Li Y, Cao C, Lee KY, Lin L. |
Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration. |
Int Immunopharmacol. 2024 Mar 30; 130:111700. |
EDB protects against ischemic stroke injury by inhibiting the proinflammatory activation of microglia/macrophages and astrocytes and through reduction by invasion of circulating immune cells, which reduces central and peripheral inflammation following stroke. |
|
| Li J, Cao W, Zhao F, Jin P. |
Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective. |
BMC Public Health. 2024 Feb 12; 24(1):436. |
Edaravone dexborneol and dl-3-n-butylphthalide are two innovative brain cytoprotective drugs from China that have been approved and widely prescribed for acute ischemic stroke. Edaravone dexborneol is a cost-effective alternative compared with dl-3-n-butylphthalide for acute ischemic stroke patients in current medical setting of China. |
|
